

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**  
Pursuant to Rule 13a-16 or 15d-16 of the  
Securities Exchange Act of 1934

**For the month of November 2022**

**Commission File Number: 001-39600**

---

**EQONEX LIMITED**  
(Translation of registrant's name into English)

**118 Piccadilly  
Mayfair, London W1J 7NW  
United Kingdom  
(Address of principal executive offices)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

---

---

## EXHIBIT INDEX

Exhibit No.	Description
99.1	<a href="#">Press Release: Receipt of Nasdaq Delisting Notice and Suspension of Trading</a>

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **EQONEX Limited**

Date: November 29, 2022

By: /s/ Chi-Won Yoon

Name: Chi-Won Yoon

Title: Chairman and Director

---

**EQONEX Announces Receipt of Nasdaq Delisting Notice and Suspension of Trading**

**Singapore - November 29, 2022:** As previously announced, EQONEX Limited (NASDAQ: EQOS) (“EQONEX” or the “Company”) received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) on November 21, 2022 that the staff of Nasdaq’s Listing Qualifications department (the “Staff”) has determined that the Company’s securities will be delisted from Nasdaq. Trading in the Company’s securities will be suspended at the opening of business on November 30, 2022.

The Company has requested a hearing before the Nasdaq Hearings Panel to appeal the Staff’s determination. The Company’s request, however, will not impact the upcoming suspension of trading in the Company’s securities.

**For investor and media inquiries, please contact:**

Investor Relations at [ir@eqonex.com](mailto:ir@eqonex.com)

---